Latest Content

Kennon McCollum, DNP, explains how multiday ES-SCLC chemotherapy regimens heighten myelosuppression risk and drive dose delays.

The FDA has approved intravenous or subcutaneous pembrolizumab combined with enfortumab vedotin-ejjv in the neoadjuvant and adjuvant MIBC settings.

Elizabeth Hubert, APRN, explains how to manage patients receiving luspatercept for low-risk myelodysplastic syndromes.

The addition of atezolizumab to BCG did not yield improved EFS compared with BCG alone in patients with high-risk non–muscle-invasive bladder cancer.

The FDA has approved sevabertinib for the treatment of patients with HER2-positive non-squamous non-small cell lung cancer.

Germline and somatic testing can inform treatment and family risk up front, but NGS is often held for recurrence, explained Courtney R. Arn, APRN-CNP.

The FDA granted standard approval to epcoritamab monotherapy and epcoritamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Nivolumab displayed significant RFS benefit compared with ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

Integrating PRO tools in survivorship care may help oncology nurses address ongoing emotional and physical needs of ovarian cancer survivors.

Here are 5 presentations that oncology APPs should know about, from patient management to practice management.

The FDA has approved a biosimilar of pertuzumab that is indicated for multiple breast cancer settings.

The FDA has approved ziftomenib for relapsed or refractory acute myeloid leukemia harboring NPM1 mutations with no alternative treatment options.